About this trial
Last updated 6 years ago
Study ID
IUGR
Status
Unknown status
Type
Observational
Placebo
No
Accepting
All
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 6 years ago
What is this trial about?
Intrauterine growth restriction (IUGR) is associated with an increase in perinatal
mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular
and endocrine complications. In Europe, about 400,000 pregnancies per year are
complicated by IUGR. However, antenatal diagnosis seems insufficient in clinical
practice, making it impossible to recognize up to 75% of foetuses with IUGR. At a time
when the use of good clinical practice has demonstrated a significant improvement in
neonatal survival without severe morbidity, foetuses with IUGR are less likely to receive
optimal care. Our hypothesis is that the rate of IUGR diagnosed underestimates the rate
of actual IUGR.
What are the participation requirements?
Inclusion Criteria
- All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant
- from 1st of january 2011 to 31 december 2017.
Exclusion Criteria
- Infants born out of the hospital and secondarily hospitalized in the hospital Femme-Mère-Enfant .
- Multiple pregnancies,
- children with congenital fetal anomalies
- pregnancies without first trimester ultrasound (to date the pregnancy)